Eutropics wins NCI contract
Eutropics will provide its BH3 profiling diagnostic assay to the NCI.
Eutropics Pharmaceuticals has been awarded a new contract to provide companion diagnostic services to the National Cancer Institute (NCI) in the US.
The agreement, signed through the institute's Small Business Initiative Research programme, will see it using its BH3 profiling diagnostic assay for treatments used in the management of patients with acute myelogenous leukaemia (AML).
The assay provides diagnostic help that can be used to inform the use of several different therapies and is currently being tested as a tool to be used alongside more experimental treatments currently in development.
It uses a biomarker that provides an understanding of whether or not cancer cells will be capable of responding to certain treatments, making it a crucial tool in deciding when to use certain treatments and which should be avoided.
"There is a very good likelihood that this BH3 profiling technology will provide an important guiding tool for treating AML," said Dr Michael Andreeff, chief of molecular hematology at MD Anderson Cancer Center and scientific advisor to Eutropics.
"We are all looking forward to its validation in the clinical studies proposed in this contract."
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...